SCHEMBL192404

SCHEMBL192404

CC(C)(C)OC(=O)N(CC(=O)OCc1ccccc1)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
NOX1 Q9Y5S8 2/20 0.46
LTA4H P09960 1/20 0.46
MAOB P27338 2/20 0.46
ALOX5 P09917 3/20 0.45
NR4A1 P22736 1/20 0.45
NR4A2 P43354 1/20 0.45
NR4A3 Q92570 1/20 0.45
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
PTGES O14684 1/20 0.44
TSPO P30536 1/20 0.44
EGFR P00533 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCD Q05655 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2574961 0.91 ALDH1A1 (0.61) ALDH1A1NOX1LTA4HMAOBALOX5
SCHEMBL191548 0.90 MAOB (0.50) ALDH1A1NOX1MAOBALOX5NR4A1
SCHEMBL8960656 0.89 LMNA (0.44) ALDH1A1MAPTL3MBTL1
SCHEMBL3379315 0.87 HPGD (0.43) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL17890894 0.86 NOX1 (0.54) ALDH1A1NOX1LTA4HMAOBALOX5
SCHEMBL193278 0.84 SMN1; SMN2 (0.43) ALDH1A1NOX1ALOX5PTGS1PTGS2
SCHEMBL3104540 0.80 NOX1 (0.50) ALDH1A1NOX1LTA4HMAOBALOX5
SCHEMBL7430134 0.80 NOX1 (0.46) ALDH1A1NOX1LTA4HMAOBALOX5
SCHEMBL29077734 0.79 L3MBTL1 (0.50) ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL4832460 0.79 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877366-B1 HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2012-01-04 EP disclosed
US-7973181-B2 Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2011-07-05 US disclosed
US-20090298924-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298924-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY HDAC1, HDAC3, HAT1 ALDH1A1 348/4885NOX1 132/4885LTA4H 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.